Print Page     Close Window     

SEC Filings

8-K
BEIGENE, LTD. filed this Form 8-K on 01/07/2019
Entire Document
 

 

Tumor Type Gastric Cancer Esophageal Cancer Head & Neck SCC Ovarian Cancer Hepatocellular Carcinoma Urothelial Cancer NSCLC MSI - H / dMMR Source ESMO - IO 2018 1 ESMO - IO 2018 1 ESMO 2017 2 ESMO 2017 3 ESMO - IO 2018 1 ESMO - IO 2018 4 ESMO - IO 2018 1 CSCO 2018 5 Median Treatment Duration -- -- 104 days (30 - 339) 71 days (29 - 540) -- 4.1 mo (0.7 - 26.3) -- 2.2 mo (0.69 - 11.1) Median Follow - up Time 4.9 mo (0.9 - 25.4) 5.2 mo (0.2 - 22.7) -- -- 10.8 mo (0.7 - 31.6) -- 11.2 mo (0.5 - 25.9) 4.4 mo (0.1 - 10.7) Median Duration of Response 8.5 mo NR -- -- 15.7 mo 18.7 mo (6.2 - 18.7) NR -- Evaluable Patients N=54 N=54 N=17 N=50 N=49 N=17 N=46 N=14 CR (Confirmed) -- 1 -- -- -- 1 -- -- PR 7 5 3 2 6 4 6 4 SD 9 14 6 20 19 3 23 4 Patients Remaining on Treatment* 3 3 3 6 5 2 7 9 ▪ Objective responses observed with limited follow - up in multiple disease - specific cohorts. NR = Not reached 41 Sources:1. Ph1A/1B data as of August 31, 2018, presented at the ESMO Immuno - Oncology 2018 Congress (Sanjeev et al); 2. Ph1 data as of June 8, 2017, presented at the ESMO 2017 Congress (Horvath et al, Abstract 389P); 3. Ph1 data as of June 8, 2017, presented at the ESMO 201 7 C ongress (Meniawy et al, Abstract 388P); 4. Ph1/2 data as of August 31, 2018, presented at the ESMO Immuno - Oncology 2018 Congress ( Shahneen et al); 5. Ph1 data as of May 11, 2018, presented at CSCO 2018. Tislelizumab Response Data in Disease - Specific Cohorts

 


© 2016 BeiGene. All Rights Reserved.